Details
| Translated title of the contribution | Recurrence of IgA nephropathy after renal transplantation |
|---|---|
| Original language | German |
| Pages (from-to) | 81-86 |
| Number of pages | 6 |
| Journal | Nieren- und Hochdruckkrankheiten |
| Volume | 36 |
| Issue number | 3 |
| Publication status | Published - Mar 2007 |
| Externally published | Yes |
Abstract
Aim of the study: In the present study, we evaluated risk factors for the development and the clinical course of recurrent IgA nephropathy (IgAN) after renal transplantation. Patients and methods: We analyzed n = 125 patients who were transplanted from 1986 to 2004 and had biopsy-proven IgAN as primary disease and n = 250 renal allograft recipients with other primary diseases. The mean follow-up period was 6.0 ± 3.6 years. Results: During follow-up, IgAN recurrence was diagnosed by transplant biopsy in n = 24 patients (19% of the cohort, 44% of the patients who underwent a transplant biopsy for any reason after the first 6 months post transplantation). The mean time from renal transplantation to the development of microscopic hematuria and histologic confirmation of IgAN recurrence was 2.8 ± 1.8 and 4.7 ± 2.6 years, respectively. Patients with biopsy-confirmed IgAN recurrence were younger compared to patients with biopsy-excluded or with no clinical signs of recurrence (37.6 ± 11 vs 44.4 ± 12 years, p < 0.05). In the Cox regression analysis, a 34% higher recurrence risk was demonstrated for every decade of age (HR 0.66, 95% CI: 0.45 - 0.96, p < 0.05). IgAN recurrence was not associated with the type of the graft (cadaveric or living donor), HLA constellation, number of acute rejection episodes or immunosuppressive and antihypertensive medications (NS). Graft survival was not influenced by the presence of IgAN recurrence (NS). There was no significant difference in graft survival between patients with IgAN and other primary diseases (NS). Conclusion: IgAN recurrence is a common complication, especially in younger renal transplant recipients, but has no impact on graft survival.
ASJC Scopus subject areas
- Medicine(all)
- Internal Medicine
- Medicine(all)
- Nephrology
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Nieren- und Hochdruckkrankheiten, Vol. 36, No. 3, 03.2007, p. 81-86.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Rekurrenz der IgA-nephropathie nach nierentransplantation
AU - Bantis, Christos
AU - Heering, P. J.
AU - Blume, Cornelia
AU - Aker, Sendogan
AU - Siekierka, Magdalena
AU - Grabensee, B.
AU - Ivens, Katrin
PY - 2007/3
Y1 - 2007/3
N2 - Aim of the study: In the present study, we evaluated risk factors for the development and the clinical course of recurrent IgA nephropathy (IgAN) after renal transplantation. Patients and methods: We analyzed n = 125 patients who were transplanted from 1986 to 2004 and had biopsy-proven IgAN as primary disease and n = 250 renal allograft recipients with other primary diseases. The mean follow-up period was 6.0 ± 3.6 years. Results: During follow-up, IgAN recurrence was diagnosed by transplant biopsy in n = 24 patients (19% of the cohort, 44% of the patients who underwent a transplant biopsy for any reason after the first 6 months post transplantation). The mean time from renal transplantation to the development of microscopic hematuria and histologic confirmation of IgAN recurrence was 2.8 ± 1.8 and 4.7 ± 2.6 years, respectively. Patients with biopsy-confirmed IgAN recurrence were younger compared to patients with biopsy-excluded or with no clinical signs of recurrence (37.6 ± 11 vs 44.4 ± 12 years, p < 0.05). In the Cox regression analysis, a 34% higher recurrence risk was demonstrated for every decade of age (HR 0.66, 95% CI: 0.45 - 0.96, p < 0.05). IgAN recurrence was not associated with the type of the graft (cadaveric or living donor), HLA constellation, number of acute rejection episodes or immunosuppressive and antihypertensive medications (NS). Graft survival was not influenced by the presence of IgAN recurrence (NS). There was no significant difference in graft survival between patients with IgAN and other primary diseases (NS). Conclusion: IgAN recurrence is a common complication, especially in younger renal transplant recipients, but has no impact on graft survival.
AB - Aim of the study: In the present study, we evaluated risk factors for the development and the clinical course of recurrent IgA nephropathy (IgAN) after renal transplantation. Patients and methods: We analyzed n = 125 patients who were transplanted from 1986 to 2004 and had biopsy-proven IgAN as primary disease and n = 250 renal allograft recipients with other primary diseases. The mean follow-up period was 6.0 ± 3.6 years. Results: During follow-up, IgAN recurrence was diagnosed by transplant biopsy in n = 24 patients (19% of the cohort, 44% of the patients who underwent a transplant biopsy for any reason after the first 6 months post transplantation). The mean time from renal transplantation to the development of microscopic hematuria and histologic confirmation of IgAN recurrence was 2.8 ± 1.8 and 4.7 ± 2.6 years, respectively. Patients with biopsy-confirmed IgAN recurrence were younger compared to patients with biopsy-excluded or with no clinical signs of recurrence (37.6 ± 11 vs 44.4 ± 12 years, p < 0.05). In the Cox regression analysis, a 34% higher recurrence risk was demonstrated for every decade of age (HR 0.66, 95% CI: 0.45 - 0.96, p < 0.05). IgAN recurrence was not associated with the type of the graft (cadaveric or living donor), HLA constellation, number of acute rejection episodes or immunosuppressive and antihypertensive medications (NS). Graft survival was not influenced by the presence of IgAN recurrence (NS). There was no significant difference in graft survival between patients with IgAN and other primary diseases (NS). Conclusion: IgAN recurrence is a common complication, especially in younger renal transplant recipients, but has no impact on graft survival.
KW - IgA nephropathy
KW - Kidney transplantation
KW - Kidney transplantation: complications
KW - Recurrence of primary disease
KW - Renal graft survival
UR - http://www.scopus.com/inward/record.url?scp=34247185251&partnerID=8YFLogxK
U2 - 10.5414/nhp36081
DO - 10.5414/nhp36081
M3 - Artikel
AN - SCOPUS:34247185251
VL - 36
SP - 81
EP - 86
JO - Nieren- und Hochdruckkrankheiten
JF - Nieren- und Hochdruckkrankheiten
SN - 0300-5224
IS - 3
ER -